158 related articles for article (PubMed ID: 10577989)
1. Access to disease modifying treatments for rheumatoid arthritis patients.
Furst DE; Breedveld FC; Burmester GR; Crofford L; Emery P; Feldman M; Kalden JR; Kavanaugh A; Keystone E; Lipsky PE; Maini RN; Moreland L; Smolen JS; Van De Putte L; Vischer T; Weinblatt M; Weissman M
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I129-30. PubMed ID: 10577989
[No Abstract] [Full Text] [Related]
2. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
Deighton CM; George E; Kiely PD; Ledingham J; Luqmani RA; Scott DG
Rheumatology (Oxford); 2006 Jun; 45(6):649-52. PubMed ID: 16527881
[No Abstract] [Full Text] [Related]
3. Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement.
Deighton C; Hyrich K
Rheumatology (Oxford); 2008 Nov; 47(11):1600-2. PubMed ID: 18784124
[No Abstract] [Full Text] [Related]
4. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
Emery P; Van Vollenhoven R; Ostergaard M; Choy E; Combe B; Graninger W; Krueger K; Matucci-Cerinic M; Navarro F; van Riel P; Settas L; Steinfeld S
Ann Rheum Dis; 2009 Apr; 68(4):456-9. PubMed ID: 19286904
[No Abstract] [Full Text] [Related]
5. Rheumatoid arthritis in 2005: which patients should receive TNFalpha antagonists and when? A point of view.
Le Loët X; Lequerré T; Vittecoq O
Joint Bone Spine; 2005 Dec; 72(6):447-50. PubMed ID: 16256398
[No Abstract] [Full Text] [Related]
6. Treatment of rheumatoid arthritis: we are getting there.
Yazici Y
Lancet; 2009 Jul; 374(9685):178-80. PubMed ID: 19560809
[No Abstract] [Full Text] [Related]
7. Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
Weinblatt ME
Ann Rheum Dis; 2005 Nov; 64(11):1529-31. PubMed ID: 16126790
[No Abstract] [Full Text] [Related]
8. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Ledingham J; Deighton C;
Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
[No Abstract] [Full Text] [Related]
9. Drug treatments for rheumatoid arthritis: looking backwards to move forwards.
Miossec P
BMJ; 2015 Mar; 350():h1192. PubMed ID: 25769296
[No Abstract] [Full Text] [Related]
10. Patient access to rheumatoid arthritis treatments.
Jönsson B
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S35-8. PubMed ID: 18157679
[TBL] [Abstract][Full Text] [Related]
11. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
Metcalfe S; Moodie P; Grocott R; Wilkinson T
N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
[No Abstract] [Full Text] [Related]
12. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A; Cohen S; Cush JJ
J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
[No Abstract] [Full Text] [Related]
13. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor alpha agents.
Martínez-Martínez MU; Cuevas-Orta E; Reyes-Vaca G; Baranda L; González-Amaro R; Abud-Mendoza C
Ann Rheum Dis; 2007 Jan; 66(1):134-5. PubMed ID: 17178761
[No Abstract] [Full Text] [Related]
14. Management of rheumatoid arthritis.
Handa R
Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
[TBL] [Abstract][Full Text] [Related]
15. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
16. Putting new disease-modifying antirheumatic drugs into perspective.
Saseen JJ
Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
[No Abstract] [Full Text] [Related]
17. [Rheumatoid arthritis: determination of the current status].
Michel BA
Z Rheumatol; 2001 Oct; 60(5):307-8. PubMed ID: 11759229
[No Abstract] [Full Text] [Related]
18. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
[No Abstract] [Full Text] [Related]
19. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis.
Hudson M; Suissa S
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):805-10. PubMed ID: 20535791
[No Abstract] [Full Text] [Related]
20. [TNF-alpha blocker in rheumatoid arthritis. Who should be treated with the new substances?].
MMW Fortschr Med; 2000 Nov; 142(44):6. PubMed ID: 11107796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
